Pandemic puts brake on strong Amgen performance

3 February 2021
amgen-logo-big

Feeling the effects of the coronavirus pandemic, Californian biotech Amgen (Nasdaq: AMGN) reported mixed results for the final quarter of 2020, with rising revenues but declining profits.

Matching analysts’ expectations, revenues were up 7% at $6.6 billion, with earnings increasing 3% to $2.2 billion, which equates to $3.81 a share.

While revenues were driven by higher volume growth, this effect was partially offset by lower net selling prices and the effects of the COVID-19 pandemic.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology